MedTrace Logo

Clinical Evaluation of the AP203 Plant Extract Mixture in Adult Patients With Increased Incidence of Viral and/or Bacterial Upper Respiratory Tract Infections

NCT06020001 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-09-11

No results posted yet for this study

Summary

The aim of the study was to assess the efficacy and safety of AP203 preparation (RESCOVIN®) in a group of patients with increased incidence to viral and/or bacterial upper respiratory tract infections.

Conditions

  • Upper Respiratory Tract Infection Bacterial

Interventions

DIETARY_SUPPLEMENT

AP203 mixture (RESCOVIN®)

Polyphenol-rich plant extracts Twice a day

DIETARY_SUPPLEMENT

AP203 mixture (RESCOVIN®)

Polyphenol-rich plant extracts Twice a day

OTHER

Placebo

Twice a day

Sponsors & Collaborators

  • AronPharma Sp. z o. o.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-14
Primary Completion
2023-04-27
Completion
2023-04-27

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06020001 on ClinicalTrials.gov